High resolution imaging using near-infrared-II fluorescence
Disclosed are methods for imaging lumen-forming structures such as blood vessels using near-infrared fluorescence in the NIR-II region of 1000-1700 nm. The fluorescence is created by excitation of solubilized nano-structures that are delivered to the structures, such as carbon nanotubes, quantum dots or organic molecular fluorophores attached to hydrophilic polymers. These nanostructures fluoresce in the NIR-II region when illuminated through the skin and tissues. Fine anatomical vessel resolution down to −30 μm and high temporal resolution up to 5-10 frames per second is obtained for small-vessel imaging with up to 1 cm penetration depth in mouse hind limb, which compares favorably to tomographic imaging modalities such as CT and MRI with much higher spatial and temporal resolution, and compares favorably to scanning microscopic imaging techniques with much deeper penetration.
1. A method of determining flow velocity of a fluid in a lumen-forming structure, comprising the steps of:
(a) delivering to said lumen-forming structure solubilized nanostructures that fluoresce in a near infrared II (“NIR-II”) region of 1000 to 1700 nm, wherein the lumen-forming structure is a blood vessel, lymph duct, bile duct, or milk duct;
(b) fluorescently exciting nanostructures from step (a) present within said lumen-forming structure;
(c) collecting NIR-II fluorescence emitted from nanostructures excited in step (b); and
(d) determining the flow velocity in a region of interest (ROI) in the lumen-forming structure by analyzing fluorescence emission collected in step (c) at a spatial resolution between 2-10 μm and a temporal resolution down to 10 msec per frame and measuring changes in average NIR-II fluorescence emission intensity over time in the ROI.
2. The method of claim 1 , wherein the analyzing comprises principal component analysis (“PCA”) of blood flow hemodynamics to assign colors to components of images and differentiate veins versus arteries.
3. The method of claim 1 , wherein said delivering is by intravenous injection, subcutaneous injection, or intramuscular injection.
4. The method of claim 1 , wherein the solubilized nanostructure is a carbon nanostructure.
5. The method of claim 4 , wherein the carbon nanostructure is a single walled nanotube (“SWNT”).
6. The method of claim 1 , wherein the solubilized nanostructure is a carbon nanostructure solubilized with polyethylene glycol (“PEG”).
7. The method of claim 1 , wherein the solubilized nanostructure is a quantum dot fluorescing in the NIR-II region.
8. The method of claim 7 , wherein the quantum dot is selected from the group consisting of Ag 2 S, PbS and Ag 2 Se.
9. The method of claim 8 , wherein the quantum dot is Ag 2 S having a diameter between 2 and 50 nm.
10. The method of claim 1 , wherein the solubilized nanostructures further comprise fluorophores that are organic small molecules fluorescing in the NIR-II region.
11. The method of claim 10 , wherein the organic small molecules are IR-1051 (6-Chlor-2-[2-[3-[(6-chlor-1-ethyl-2H-benzo[cd]indol-2-yliden)-ethyliden]-2-phenyl-1-cyclopenten-1-yl]-ethenyl]-1-ethyl-benzo[cd]indolium tetrafluoroborate), IR-26 (4-(7-(2-phenyl-4H-1-benzothiopyran-4-ylidene)-4-chloro-3,5-trimethylene-1,3,5-heptatrienyl)-2-phenyl-1-benzothiopyrylium perchlorate), and IR-1061 (4-[2[2-Chloro-3-[(2,6-diphenyl-4H-thiopyran-4-ylidene)ethylidene]-1-cyclohexen-1-yl]ethenyl]-2,6-diphenylthiopyrylium tetrafluoroborate).
12. The method of claim 1 , wherein imaging is done at a penetration depth between 5 mm-1 cm.
13. The method of claim 12 , wherein the solubilized nanostructure is a carbon nanostructure.